Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2024 - Mental Daily. All Rights Reserved.
Clinical

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

Staff Writer
Staff Writer 3 years ago
Updated 2022/05/18 at 1:17 AM
Share
SHARE

A new study by two experts at Northwestern University has shown that an experimental drug known as NU-9 can be more effective for treating amyotrophic lateral sclerosis (ALS) than existing FDA-approved drugs.

As emphasized in the latest findings in Scientific Reports, the experimental drug NU-9 lengthened the axons of diseased neurons in the rodent subjects tested.

“Here, we describe a novel in vitro platform that takes advantage of an upper motor neurons (UMNs) reporter line in which UMNs are genetically labeled with fluorescence and have misfolded SOD1 toxicity,” according to the study’s authors.

“We report that NU-9, an analog of the cyclohexane-1,3-dione family of compounds, improves the health of UMNs with misfolded SOD1 toxicity more effectively than riluzole or edaravone, -the only two FDA-approved ALS drugs to date-.”

The findings suggest that the drug’s efficacy revolves around its ability to improve axon outgrowth and axon health.

“This is very important for connecting the brain and the spinal cord and for revitalizing the motor neuron circuitry that degenerates in patients,” said the study’s lead author in a news release.

Photo: Freepik

You Might Also Like

Study explores victim-blaming, manipulation, and denial as tactics used by terrorists

Study finds majority of prisoners receive no visitors, possibly affecting recidivism

Dementia risk factors differ by ethnicity, according to new research

Researchers investigate how endocannabinoids regulate the brain’s stress response

Study shows the risk of eating disorders may be lower among vegans

TAGGED: axon health, NU-9, ALS
Staff Writer May 17, 2022
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article How adolescent binge drinking can significantly affect brain function
Next Article New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

Recommended

Clinical

Study explores victim-blaming, manipulation, and denial as tactics used by terrorists

1 Min Read
Clinical

Study finds majority of prisoners receive no visitors, possibly affecting recidivism

2 Min Read
Clinical

Dementia risk factors differ by ethnicity, according to new research

2 Min Read
Clinical

Researchers investigate how endocannabinoids regulate the brain’s stress response

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
  • Mental Health
Follow US

© 2024 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?